Table 1.

Plasma MMP1 and MMP8 levels in relation to standard prognostic markers.

Characteristics	MMP1 (ng/ml)		OR (95% CI)	p*	MMP8 (ng/ml)		OR (95% CI)	p*
	Median (IQR)	n			Median (IQR)	n
all patients	2.0 (0.8–3.7)	202			10.5 (4.4–19.1)	198
menopausal status
premenopausal	2.0 (0.5–4.0)	70	1.02 (0.91–1.13)	0.67	14.8 (5.4–20.8)	70	0.98 (0.95–1.00)	0.06
postmenopausal	2.0 (1.0–3.5)	122			10.0 (4.2–18.8)	117
unknown	2.2 (1.3–3.0)	10			6.0 (3.6–13.4)	11
breast cancer
inflammatory	1.1 (0.6–2.0)	21	0.74 (0.56–0.98)	0.02	6.3 (3.5–8.5)	19	0.90 (0.83–0.97)	0.007
non-inflammatory	2.2 (0.8–3.9)	181			11.0 (4.7–20.5)	179
non-inflammatory breast cancer patients
Primary tumour size
pT1	2.4 (1.1–4.2)	79	1.11 (1.00–1.23)	0.07	10.2 (3.8–20.5)	76	0.99 (0.97–1.01)	0.14
pT2	2.2 (0.8–3.7)	76			11.0 (4.6–18.8)	77
pT3	1.3 (0.6–2.2)	26			16.4 (6.4–24.0)	26
axillary lymph node status
pN0	2.3 (1.1–4.1)	86	1.04 (0.94–1.15)	0.18	7.5 (3.5–19.1)	83	0.99 (0.97–1.01)	0.003
pN1	1.9 (0.8–3.6)	67			13.4 (8.0–22.5)	66
pN2	0.9 (0.1–3.4)	19			18.0 (12.5–22.0)	19
pN3	2.7 (1.9–4.6)	9			5.7 (2.9–8.9)	11
histologic grade
well (G1)	3.4 (1.0–4.6)	17	0.99 (0.90–1.10)	0.14	4.9 (3.3–20.9)	16	1.00 (0.98–1.03)	0.37
moderatly (G2)	1.6 (0.6–3.0)	70			15.2 (4.8–21.6)	68
poorly (G3)	2.2 (1.1–4.0)	94			11.0 (5.4–18.9)	95
oestrogen receptor
Negative	1.6 (0.2–3.7)	21	1.13 (0.92–1.39)	0.31	8.9 (4.3–22.9)	22	1.00 (0.97–1.04)	0.93
Positive	2.2 (0.9–4.0)	160			11.3 (5.1–20.1)	157
progesteron receptor †
Negative	2.0 (0.2–3.5)	32	1.13 (0.95–1.35)	0.29	12.3 (4.9–23.5)	32	0.98 (0.95–1.00)	0.30
Positive	2.2 (0.9–4.0)	148			10.9 (4.7–19.4)	146
Her2 overexpression
Negative	2.2 (0.8–3.8)	158	0.97 (0.82–1.14)	0.79	10.9 (4.9–20.2)	156	1.03 (1.00–1.06)	0.39
Positive	1.8 (1.1–4.4)	23			13.7 (3.2–25.7)	23

*p for Mann-Whitney U test or Kruskal-Wallis test. † Progesteron receptor status is unknown for one patient in both MMP1 and MMP8 analyses.

Note: Her2 status was defined by immunohistochemistry and dual-colour FISH analyses

IQR, interquartile range; OR, odds ratio